To Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study
Latest Information Update: 06 Dec 2022
At a glance
- Drugs HPP 737 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Newsoara Biopharma
- 29 Jun 2021 According to a vTv Therapeutics media release, it will be presenting data from this trial in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 - July 3, 2021 in Stockholm, Sweden.The poster will be added to vTv's website following the presentation and will be available at: https://vtvtherapeutics.com/pipeline/hpp737/
- 17 Feb 2021 Results presented in a vTv Therapeutics media release.
- 17 Feb 2021 Status changed from recruiting to completed, according to a vTv Therapeutics media release.